Platinum-based drugs induce phenotypic alterations in nucleoli and Cajal bodies in prostate cancer cells.
Enkhzaya BatnasanMinttu KärkkäinenSonja KoivukoskiNithin SadeeshSylvain TollisPekka RuusuvuoriMauro ScaravilliLeena LatonenPublished in: Cancer cell international (2024)
Our findings provide insight into the heterologous responses of prostate cancer cells to different platinum drug treatments and indicate Coilin and TDP-43 as stress mediators in the varied outcomes. These results help understand cancer drug responses at a cellular level and have implications in tackling heterogeneity in cancer treatment outcomes.